TOPICALLY & TRANSDERMALLY STUDIED PEPTIDES / COLOPHON
About This Reading Bench
A citation-anchored orientation to research peptide fundamentals, organised by how each compound reaches the body.
What Topical Peptides is
Topical Peptides is a reading bench organised around one question: how does a given research peptide actually get into, or onto, the body — and what does that route reveal about how it works? It reads the published science on three compounds that answer that question three different ways. GHK-Cu, a copper-binding tripeptide with directly measured transdermal delivery, leads the bench; semaglutide, a GLP-1 receptor agonist built for the bloodstream, and thymosin alpha-1, a thymic immune peptide given only by injection, supply the contrast.
The point isn't that the three treat the same thing or share a mechanism — they plainly don't. It is that reading them side by side turns delivery route from an afterthought into a real lesson in fundamentals: why some peptides can be rubbed onto skin and measured crossing it, why others need a fatty-acid tail and a week-long half-life just to survive in blood, and why others are studied by injection alone because their targets were never reachable any other way. Each compound has its own page, a comparison page lines the three up together, and one shared references list gathers every source.
How it is compiled
Two principles govern what appears here. First, every research claim is anchored to a numbered citation on the references page — peer-reviewed journal articles and clinical-trial publications, with DOIs and PubMed links where available. Where a finding comes from a review rather than a primary study, or from a database analysis rather than a directly measured tissue outcome, that distinction is stated in the same sentence, not buried in a footnote.
Second, the evidence is described at its actual strength and scale. GHK-Cu's human evidence comes from small controlled trials — some in the tens of participants — alongside extensive cell-culture and gene-expression work; semaglutide's comes from multi-thousand-participant randomized trials; thymosin alpha-1's is the most mixed, spanning decades of smaller positive signals and one large, rigorous, null 2025 trial. This desk does not average those differences away or present them as equivalent; it says plainly which kind of evidence supports which claim.
What it is not
This bench sells nothing and treats no one. Topical Peptides is not a pharmacy, a clinic, or a supplier of any kind; it does not stock, source, or broker GHK-Cu, semaglutide, thymosin alpha-1, or anything else, and it holds no affiliate tie to any manufacturer, telehealth provider, or research-chemical seller. It diagnoses no condition, prescribes no treatment, and names no dose, schedule, or route for any person.
The regulatory footing differs by compound: semaglutide is an approved prescription medicine available only through licensed providers; thymosin alpha-1 is an approved drug in some countries but investigational in the United States; GHK-Cu is a legal cosmetic ingredient in topical form, with any other route unapproved and unstudied in humans. Readers wanting clinical guidance should see a licensed provider. Editorial mail about citations, corrections, or new research is welcome on the contact page — but medical advice is the one thing this bench can't send back.